AMG-199 is under clinical development by Amgen and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMG-199’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMG-199 is under development for the treatment of solid tumors including colorectal cancer, pancreatic ductal adenocarcinoma, gastric cancer and metastatic gastroesophageal junction (GEJ) adenocarcinoma. It is a bi-specific T cell engager (BiTE) antibody. The bi-specific antibody recruits CD3 antibody in one arm and MUC17on the other arm. It is administered through intravenous route.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of AMG-199’s drug-specific PTSR and LoA scores, buy the report here.